FcgRIII Deficiency and FcgRIIb Defeciency Promote Renal Injury in Diabetic Mice.
FcgRIII Deficiency and FcgRIIb Defeciency Promote Renal Injury in Diabetic Mice. Biomed Res Int. 2019;2019:3514574 Authors: Zhang R, Wang T, Yin Q, Zhang J, Li L, Guo R, Han Q, Li H, Wang Y, Wang J, Gurung P, Lu Y, Cheng J, Bai L, Zhang J, Liu F Abstract The immune system is involved in the development of diabetes complications and IgG Fc gamma receptors (FcgRs) are key immune receptors responsible for the effective control of both humoral and innate immunity. We investigated the effects of members of the FcgR superfamily into both the streptozotocin plus high fat-induced type 2 diabetes and high fat diet (HFD) models. FcgRIII-/- diabetic mice and FcgRIIb-/- diabetic mice had elevated levels of serum creatinine compared with wildtype (WT) diabetic mice. Renal histology of diabetic FcgRIII knockout and FcgRIIb knockout mice showed mesangial expansion and GBM thickening; the mechanistic study indicated a higher expression of TGF-β1, TNF-α, and p-NFκB-p65 compared with wild type mouse. The HFD mouse with FcgRIII knockout or FcgRIIb knockout had increased biochemical and renal injury factors, but oxLDL deposition was higher than in FcgRIII-/- diabetic mice and FcgRIIb-/- diabetic mice. In vitro we further examined the mechanism by which the Fc gamma receptor promoted renal injury and transfected glomerular mesangial cells (GMCs) with FcgRI siRNA attenuated the level of TGF-β1, TNF-α expression. In summary, FcgRI knockdown downregu...
In conclusion, Chinese postmenopausal women with T2DM had a similar risk of incident VFs, but a significantly higher risk of incident non-VF, compared to women without DM. Higher BMI did not modify the effect of T2DM on risk of VFs, but it increased the association be tween T2DM and risk of non-VFs. LS BMDT-score was similarly and negatively associated with VF risk in T2DM and non-DM women and appear to be useful for clinical evaluation of VF risk.
The evidence is clear. Bariatric surgery provides wide-ranging benefits to adolescents with obesity and type 2 diabetes, says Dr Louise Baur.Medscape Diabetes &Endocrinology
Conditions: Type 2 Diabetes; Diabetic Nephropathy Intervention: Drug: SGLT2 Inhibition Sponsor: Zhongshan Hospital Xiamen University Recruiting
Conditions: Obesity; Diabetes Mellitus, Type 2; Insulin Resistance Intervention: Other: Methylation status Sponsor: University of Arizona Recruiting
Condition: Childhood Obesity Intervention: Behavioral: Evaluation of whiteboard videos Sponsors: The Hospital for Sick Children; University of Ottawa Not yet recruiting
TYPE 2 diabetes requires a person to revise their dietary decisions in a bid to control their blood sugar levels. Fortunately, certain foods have been shown to keep blood sugar levels in check, including a certain vegetable.
A new study from the University of Geneva, in Switzerland, found having a fatty liver might be another cause of type 2 diabetes because it can produce glucose on its own.
The Metabolic Syndrome may be tentatively defined as the clustering of several metabolic risk factors in the same individual. A progressively higher number of children and adolescents is affected by this syndrome worldwide, mainly as a consequence of the constant increase of the prevalence of obesity and sedentary habits. As obesity, the chance that the metabolic syndrome traks into adulthood is high. Moreover, the evidence of an association between the duration of the exposition to metabolic risk factors and morbidity and mortality justifies early treatment and prevention of the metabolic syndrome in both children and ado...
AbstractHeart failure is one of the major cardiovascular complications in patients with type 2 diabetes mellitus (T2DM) and increases the risk of morbidity and mortality. Although active management for heart failure is needed in patients with T2DM, traditional treatment and some new class of antihyperglycemic drugs, such as glucagon-like peptide-1 receptor agonists or dipeptidyl peptidase-4 inhibitors, could not reduce the risk of heart failure. Recent major trials demonstrated sodium –glucose co-transporter-2 (SGLT2) inhibitors improve prognosis of T2DM patients through prevention of heart failure. Both heart failur...